Baxalta Inc
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY15 | FY14 | FY13 | |
|---|---|---|---|
| Revenue | $1.36B | $1.33B | $5.55B |
| Operating income | — | — | — |
| Net income | $272.0M | $358.0M | $1.29B |
| Total assets | $12.33B | $8.58B | — |
| Total liabilities | — | — | — |
| Equity | $3.92B | $5.75B | $5.18B |
| EPS (diluted) | $0.40 | $0.52 | $1.89 |
| Shares out. | 679.3M | 0 | 681.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2015- Operating margin
- —
- Net margin
- 20.0%
- Return on equity
- 6.9%
- Return on assets
- 2.2%
- Return on capital (ROCE)
- —
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $5.78
- Revenue growth (YoY)
- 2.4%
- Net income growth (YoY)
- −24.0%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2015- Accruals / assets
- −4.3%clean
- Piotroski F-Score
- 4/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 good- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Goff BrianOfficer — EVP and President, Hematology | Jun 3, 2016 | Grant | 2,881 | $0.00 |
| Hombach Robert J.Officer — EVP. CFO and COO | Jun 3, 2016 | Grant | 16,356 | $0.00 |
| Glasspool JohnOfficer — See Remarks | Jun 3, 2016 | Grant | 1,461 | $0.00 |
| Leonardi JacopoOfficer — EVP and President, Immunology | Jun 3, 2016 | Grant | 1,033 | $0.00 |
| Stroucken Albert P LDirector | Jun 3, 2016 | D | 22,194 | — |
| Rosa-Bjorkeson DagmarOfficer — EVP and President, Biosimilars | Jun 3, 2016 | D | 71,293 | — |
| Edwards Peter GOfficer — SVP and General Counsel | Jun 3, 2016 | D | 216,343 | — |
| Fosler Gail DDirector | Jun 3, 2016 | D | 39,364 | — |
| Orloff John JOfficer — See Remarks | Jun 3, 2016 | D | 96,384 | — |
| Forsyth John DDirector | Jun 3, 2016 | D | 27,827 | — |
| Meek David D.Officer — EVP and President, Oncology | Jun 3, 2016 | D | 51,640 | — |
| Hantson LudwigOfficer — President and CEO | Jun 3, 2016 | Grant | 16,356 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsJun 3, 2016
- Shareholder vote · Other material eventMay 27, 2016
- Results of operations · Regulation FD disclosureApr 28, 2016
- Director / officer change · Other material eventApr 7, 2016
- Other material eventMar 31, 2016
- Results of operations · Regulation FD disclosureFeb 16, 2016
- Entered a material agreement · Modified shareholder rights · Director / officer changeJan 11, 2016
- Results of operations · Regulation FD disclosureOct 29, 2015
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-15DFORM 15-15DFeb 7, 2019
- SC 13G/AFORM SC 13G/AFeb 5, 2018
- SC 13G/AFORM SC 13G/AFeb 6, 2017
- SC 13G/AFORM SC 13G/AFeb 6, 2017
- 11-KJun 28, 2016
- 15-12BJun 13, 2016
- SC 13GJun 7, 2016
- 4FORM 4 SUBMISSIONJun 7, 2016
- 4FORM 4 SUBMISSIONJun 7, 2016
- 4FORM 4 SUBMISSIONJun 7, 2016
- 4FORM 4 SUBMISSIONJun 7, 2016
- 4FORM 4 SUBMISSIONJun 7, 2016
- 4FORM 4 SUBMISSIONJun 7, 2016
- 4FORM 4 SUBMISSIONJun 7, 2016
- 4FORM 4 SUBMISSIONJun 7, 2016
Corporate family
Spun off from Baxter International IncBAX · Jul 1, 2015
From the spin-off filings we track. Follow a company to walk its own history.
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.